Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Its past my bedtime and after 3 glasses of wine, I'm unable to find a video clip of our Arthur P. Bertolino making a presentation to either a conference or to a media outlet. I leave it to our night owls, our west coasters or our Hawaiian posters who might not be impaired, to find such historical evidence....
The PR said he's been a "contributor to major media broadcasts".
Let's see what we've got.
gh
I woke up this morning and I couldn't get back to sleep; I was grinning. I dreamt of our Mr. Sullivan questioning Mr.Kim Rosen in court. KR was squirming, sweating, tugging at his collar and looking like a bug eyed Rodney Dangerfield. The question was simple, "When did you first read the Mako article"
Not that Mr. Sullivan needs our help, but for our weekend entertainment I invite others to devise the most uncomfortable, incriminating questions to be asked of KR.
gh
What about the possibility of CRIMINAL action against Rosen/SA under the RICO statutes. Lengthy incarceration, and reimbursement to CTIX would seem appropriate and would serve as a deterrent.
I understand Mr. Sullivan has relevant experience with such miscreants.
I want them to SUFFER the consequences of their actions.
Go get 'em Mike!
gh
I hope they do!
gh
"7 minutes to close. Looks like there are some nervous nellies that aren't willing to hold over the week end. Hope they don't have to kick themselves in the ass come Monday morning."
Also down the road, why not use Kevetrin as a cancer 'vaccine'?
If K is harmless, who would not want it?
Responding to: Someone asked me the other day if Kevetrin could be used as a continuous maintenance therapy for folks who have had partial or complete remission of certain cancers... Has Leo or Dr Menon mentioned anything like this?
gh
The Black Knight:
My understanding of pharma law is that if P gets approval as safe and effective for mild or moderate cases of psoriasis, it would be legal and ethical for a doc to prescribe it, even for a severe case. This would seem a reasonable alternative to an expensive and worrisome biologic with known unpleasant side effects.
Am I correct?
gh
Anyone correct me if I'm wrong:
If Rosen's latest filing is the some old load of crap, the judge could dismiss the complaint now and not wait for Sullivan's response.
gh
Thanks Cabel for he list of Dapto side effects; truly frightening.
The cost of these plus the week in the hospital--which is the obvious choice? Brilacidin!
gh
If I lived in the NYC area, I would try to be in the courtroom when the suit is dismissed, the judge gives them a good tongue-lashing and the scumbags slink out of the courtroom only to be met by the SEC and Federal marshals.
PRIVATE institutions which stay below the reporting thresholds might be here and we would never know it.
25 K of Gold: "Free shares to whoever can say Finansinspektionen 10×fast"
Its easier to pronounce than thioureidobutyronitrile :)
gh
Capitalism
You posted "Bottom line Leo is not a saint, he's just another typical American capitalist, lol"
Leo may or may not be a saint, but Capitalism can be the the tool for people to change the world. It brought us out of the caves, or serfdom or tribalism to the affluence of the modern world. If that's not a miracle, I don't know what is.
God bless CTIX
gh
Does anybody know if anyone at CTIX has contacted the former shareholders of Polymedics to invite them to participate in our impending bonanza? This would include not just the shareholders at the time of Polymedics' demise, but those who sold out before the bitter end. After 2 years, they might wish to get back onto the defensin-mimetics horse for the wild ride that we longs expect.
gh
The Phase2 Brilacidin trial was a single dose injection, if memory serves, so at most Phase 3 treatment would be a mater of hours with a follow up period of weeks. The trial could be over very quickly in my opinion, especially if all goes well. I would think FDA would be anxious to approve, barring outside influence. :)
gh
Leo is not destroying shareholder value. Mako and those who spread F.U.D. are.
gh
The company is NOT crippled. Cash is on hand. Credit is available. Shelf is full. Trials are successful and moving forward.
The door is open for unhappy investors to leave!
gh
Big K,
Thanks for the corrections and the details; I was not completely wrong.
I maintain my sentiment: God Bless Dr. Menon and the CTIX team!
This is not just a financial investment.
gh
You said: "Those are the risks. No one can change the outcome of drugs that don't perform, which is why a lot of people keep saying that it is the science that matters."
But correct me if I'm wrong, wasn't Brilacidin's initial trial under Polymedics somewhat of a failure? Only after tweaking the dosage and other feats of scientific legerdemain under CTIX's ownership did the drug not cause patient's elevated blood pressure leading to Polymedics' demise. Its late, I'm old and I had a stroke about a year ago so my memory is none too reliable, but our scientific talent, Dr. Menon, did change a drug that had failed into a potential world changing Bonanza for us shareholders, and newfound health for millions.
I tire of all the naysayers and spreaders of F. U. D.
We have a gold mine here; enjoy the ride!
God Bless Dr. Menon and all the CTIX team!
gh
PC,
I think you're wrong on the timing of a brilacidin partnership or other deal.
Correct me if I'm wrong, but I thought Leo said some kind of a deal was awaiting the beginning of a B Phase 3 trial, not the end of the trial. Someone please clarify this for me.
gh
I believe you are correct bejamin, that Leo has stated that a deal could be reached AFTER the START of B Phase 3, not after the conclusion. This is one reason that checking for such a PR is the first thing on my to do list every day. Its also the reason that I hold a major portion of my net worth in CTIX, rather than selling and waiting to get back in; once the news hits, I expect a dramatic spike in the share price, making re-entry expensive, both financially and psychically.
However low it goes or whatever crap the bastar%&s post about us I'm not selling.
My boat is fully loaded. My investment decisions are: 1) At what low price will I overload my boat? and 2) At what high price will I begin to take PROFITS!?
gh
How about a group of angry terminal cancer patients picketing Kim & Rosen's office on Madison Ave. ? Film at eleven!
gh
How about instead of just filing a complaint against the ambulance chasers, file a lawsuit? Of course one would probably need an attorney... :)
gh
We should be getting the monthly announcement of patient enrollment for our phase 3 trial of multikine in the next day or two. Here's hoping for continued good numbers!
Also, if there are newly added trial sites, that would help to speed the trial along.
gh
Fletch, please tell us when and where did Leo's letter that you posted originate?
tx,
gh
I really don't feel like posting......but I will......many here said the below short selling issue was not real......The chart recently looked.........very odd or way over down to me.......pay most attention to the first paragraph,
Fletch
My Fellow Cellceutix Shareholders,
Many investors are aware that when a company announces plans to uplist to a senior exchange, they attract and become vulnerable to those engaged in short selling. These people/funds take short positions trying to drive a stock down and hope for a reverse split to be necessary to meet share price requirements for the senior exchange. The companies are viewed as easy prey, as often these companies need to uplist in order to meet conditions of a financing.
We’re not splitting our stock. We have cash on hand and an equity line. Long term shareholders know we’ve been through these short attacks before and each time the stock recovered and reached new highs. As far as the uplist, it is in progress with NASDAQ.
If one has doubt as to the potential of our lead anti-cancer drug Kevetrin, I encourage you to read this morning’s press release disclosing that the Institutional Review Board (IRB) approved additional enrollment for our trial of Kevetrin for solid tumors at Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. Typically, we are not inclined to release news on Fridays, but we wanted to share this – what we consider to be fantastic – news immediately with our shareholders.
Understand that Harvard Cancer Centers sit among the elite in the country for cancer research. The Scientific Review Committee and IRB had no obligation to allow for additional enrollment in our trial. After treating forty patients, would they want to treat more patients with a drug candidate that they don’t believe has potential? Of course not. We interpret the IRB approval as a strong vote of confidence as to the safety and potential impact of Kevetrin.
Thank you for your continued support.
Sincerely,
Leo Ehrlich, Chief Executive Officer, Cellceutix
Still no response from Leo.
gh
Why has the company not responded?
gh
I just loaded my little boat with the stock and the warrants, hoping for big results, in both the scientific and arbitration trails.
gh
I just saw this article on the National Review Website : http://www.nationalreview.com/article/421504/traumatic-brain-injury-intrepid-spirit-centers?utm_source=jolt&utm_medium=email&utm_term=Jolt&utm_campaign=Jolt07232015 and sent the author, James MacGuire, an email calling his attention to AEMD.
gh
CTIX has had a remarkable week. I'd love to see what your charts tell you...
We expect more good news in the near future.
thanks,
gh
Florida's governor has signed the "Right To Try" bill into law:
http://www.myfloridahouse.gov/Sections/Documents/loaddoc.aspx?FileName=h0269z1.HIS.DOCX&DocumentType=Analysis&BillNumber=0269&Session=2015
Several other states have similar laws. Is this a viable path forward, after the conclusion of Kevetrin phase one?
gh
I just googled and binged Dr. Shapiro. I was reminded that he's one of the top guys at one of the top medical institutions, working on 'OUR' Kevetrin. He'll probably know and be highly regarded by hundreds if not thousands of ASCO participants. He'll be presenting the two and 1/2 years of our success in activating the p53 'guardian angel' gene. They've worked and failed at this for 35 years...till now!
I think there'll be a lot of folks excited at ASCO.
Thanks Dr. M. and Leo.
gh
Potentially good news. Fingers crossed!
News Feature | April 13, 2015
FDA Issues Two Guidance Docs Aimed At Speeding Access To New Medical Devices
By Suzanne Hodsden
FDA
The FDA recently released two guidance documents that it believes will accelerate U.S. market entry for certain medical devices.
The first guidance outlines the Expedited Access Pathway (EAP) for medical devices that treat life-threatening or irreversibly debilitating diseases or conditions with few or no alternative treatment options. Under the EAP, first announced in early 2014, FDA will work closely with manufacturers to reduce timeframes and costs associated with premarket approval.
The second guidance clarifies current FDA policy on pre- and postmarket data collection. It explains situations in which postmarket data collection is appropriate for premarket approval (PMA) applications, both in EAP and non-EAP situations, and provides numerous examples.
Under the terms of the EAP, a device manufacturer may submit an application for the special designation if no other alternative treatment exists or if the device uses a novel technology that outperforms existing treatment options. Consideration will also be granted to devices when early availability serves the patient’s best interest.
The EAP guidance specifically applies to PMA or de novo applications and will “more interactive communications during device development and more interactive review of Investigational Device Exemptions (IDEs), PMA applications, and de novo requests,” resources permitting.
If accepted, the device will be given priority status and could be assigned an FDA case manager. The FDA and the manufacturer will also work together to create a data development plan (DDP) that could shift the burden of some premarket data requirements to postmarket.
Jeff Shuren, director of the Center for Devices and Radiological Health (CDRH), explained in a blog post that the DDP “will shift premarket data collection to the post-market setting, to the extent appropriate, taking into account the public health benefit of these devices, while still meeting the U.S. approval standard of reasonable assurance of safety and effectiveness.”
Shuren explained that the FDA will be willing, in some cases, to accept a reasonable degree of predictability based on data collected from surrogate or intermediate endpoints under the condition that the manufacturer provide more conclusive data postmarket.
“Under the EAP, FDA may accept a greater degree of uncertainty if it is sufficiently balanced by other factors, including the probable benefits to having earlier access to the device,” said Shuren in the blog.
Janet Trunzo, the senior executive vice president for technology and regulatory affairs at the Advanced Medical Technology Assocation (AdvaMed), told Bloomberg BNA that she “commends the agency for its efforts to explore supplementary review pathways to provide more timely patient access to technologies.”
However, some experts believe that these new developments are indicative of an FDA that is feeling pressure from Congress to expedite medical products at the expense of safety. Diana Zuckerman, president of the National Center for Health Research, told Bloomberg BNA that these new measures could “weaken safeguards that are intended to protect patients from unsafe medical products.”
Furthermore, a blog post published by the consulting firm Emergo Group warned that the value of the program would hinge on FDA’s ability to provide the necessary resources.
“How extensive EAP features are for registrants, however, depends on the availability of agency resources — something manufacturers should keep in mind when deciding whether to sign up for EAP review,” it stated.
The program will be up and running on April 15, 2015,when the FDA will begin accepting EAP applications. Manufacturers can expect a decision or request for additional information thirty days following submission.
http://www.meddeviceonline.com/doc/fda-issues-two-guidance-docs-aimed-at-speeding-access-to-new-medical-devices-0001
Lets just have a cascade of good results on our many opportunities that will drive up the price enough to avoid the unattractive prospect of a reverse split--that hardly ever works out.
gh
Check out IHub post #24 from march 14, 2006. This Popular Science article caused me to invest. If the #$$@^%&! FDA would get out of the way, we could all be rich!
gh
I've owned AEMD for many frustrating years. I remember an outbreak of eastern equine encephalitis that seemed like a golden opportunity, but alas.....
gh
Havendale,
I look at a glass (MORE THAN) half full.
We still have the opportunity buy at ridiculously low prices, as you just did. Soon our discount will be unavailable.
gh
I should say WAY MORE!
gh
I just sent Dr. Schaffner this email:
Dear Dr. Schaffner,
I just saw your CNBC interview and was disappointed that you seem to be unaware of the new antibiotic, BRILACIDIN, which has just successfully completed a phase 2 trial treating skin infections. Cellceutix Corperation will presenting to the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held in Copenhagen, Denmark from April 25-28, 2015.
Read about CTIX here: http://www.cellceutix.com/
Thank you for your attention,
George Harvey ( a happy shareholder of CTIX)
gh
I know a middleageed woman who survived breast cancer 12 years ago with the help of surgery, chemo and radiation treatment. Now as is not uncommon, she has been diagnosed with Chronic Myeloid Leukemia(CML). I know that we have trials planned at the U of Bologna for Acute Myelogenous Leukemia (AML).
I'm wondering if these trials are successful, will CML be included as an indication for Kevetrin, or are these 2 forms of leukemia different and thus require further testing?
gh
Shortcut to victory!
See this NY Times editorial: http://www.nytimes.com/2015/02/12/opinion/quicker-access-to-experimental-drugs.html?_r=0 It renews hope for 'compassionate use' for a drug after Phase 1 trials establish safety.
Kevetrin.
Brilacidin.
Lets start saving lives!
gh